Literature DB >> 8231026

Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition.

V Kon1, A Fogo, I Ichikawa.   

Abstract

We studied the effects of interruption of the renin-angiotensin system (RAS) in rats that were volume depleted by water deprivation for 48 hours (AWD) with/without furosemide (AWD + F), a condition known to activate RAS. Following baseline micropuncture, AWD rats (N = 6) were treated with a specific angiotensin II type 1 receptor antagonist (AIIRA; 4 mg/kg body wt bolus i.v. and then continuous infusion) and glomerular hemodynamics compared to those obtained during angiotensin I converting enzyme inhibitor treatment (ACEI; 24 mg/kg bolus i.v. and then continuous infusion). Systemic blood pressure decreased equally following AIIRA and ACEI. Single nephron glomerular filtration rate (SNGFR) increased from baseline following AIIRA (24 nl/min vs. 30, P < 0.025). While a decrease in efferent arteriolar resistance (RE) reduced glomerular capillary pressure (PGC; 67 mm Hg vs. 60, P < 0.05), this change in RE together with decrease in afferent arteriolar resistance (RA), enhanced glomerular plasma flow rate (QA; 80 nl/min vs. 111). Antagonizing angiotensin II receptor increased QA which, together with the tendency to increase glomerular capillary ultrafiltration coefficient, Kf, served to improve glomerular filtration. By contrast, although inhibition of the angiotensin I converting enzyme caused greater vasodilatation, no increase in SNGFR occurred. The lack of response in filtration after ACEI was due to a further fall in PGC to 52 mm Hg (P < 0.01 vs. AIIRA), reflecting profound reduction in RE. Since ACEI but not AIIRA potentiates bradykinin activity we examined effects of a specific bradykinin antagonist (Hoe).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8231026     DOI: 10.1038/ki.1993.279

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

Review 1.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 2.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 3.  Drug selection for optimal treatment of hypertension in the elderly.

Authors:  E Shammas; K Dickstein
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 4.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

5.  Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.

Authors:  F Tomoda; R A Lew; A I Smith; A C Madden; R G Evans
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 6.  New insights into the renin-angiotensin system and hypertensive renal disease.

Authors:  A B Fogo
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

7.  Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.

Authors:  C V Ram; P Vergne-Marini
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 8.  The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Authors:  G Neil Thomas; Paul Chan; Brian Tomlinson
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

9.  Intratubular Renin-Angiotensin System in Hypertension.

Authors:  Yuki Suzaki; Minolfa C Prieto-Carrasquero; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006

Review 10.  Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.

Authors:  B Pitt; P Chang; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.